Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Mol Metab ; 72: 101726, 2023 06.
Article in English | MEDLINE | ID: mdl-37062524

ABSTRACT

OBJECTIVE: Cancer cells use glycolysis for generation of metabolic intermediates and ATP needed for cell growth and proliferation. The transcription factor C/EBPß-LIP stimulates glycolysis and mitochondrial respiration in cancer cells. We initially observed that high expression of C/EBPß-LIP makes cells vulnerable to treatment with the glycolysis inhibitor 2-deoxyglucose. The aim of the study was to uncover the involved mechanisms of C/EBPß-LIP induced sensitivity to glycolysis inhibition. METHODS: We used genetically engineered cell lines to examine the effect of C/EBPß-LIP and -LAP protein isoforms on glycolysis and NADH/NAD+ metabolism in mouse embryonic fibroblasts (MEFs), and triple negative breast cancer (TNBC) cells that endogenously express high levels of C/EBPß-LIP. Analyses included assays of cell proliferation, cell survival and metabolic flux (OCR and ECAR by Seahorse XF96). Small molecule inhibitors were used to identify underlying metabolic pathways that mediate sensitivity to glycolysis inhibition induced by C/EBPß-LIP. RESULTS: The transcription factor C/EBPß-LIP stimulates both glycolysis and the malate-aspartate shuttle (MAS) and increases the sensitivity to glycolysis inhibition (2-deoxyglucose) in fibroblasts and breast cancer cells. Inhibition of glycolysis with ongoing C/EBPß-LIP-induced MAS activity results in NADH depletion and apoptosis that can be rescued by inhibiting either the MAS or other NAD+-regenerating processes. CONCLUSION: This study indicates that a low NADH/NAD+ ratio is an essential mediator of 2-deoxyglucose toxicity in cells with high cytoplasmic NAD+-regeneration capacity and that simultaneous inhibition of glycolysis and lowering of the NADH/NAD+ ratio may be considered to treat cancer.


Subject(s)
Aspartic Acid , CCAAT-Enhancer-Binding Protein-beta , Animals , Mice , CCAAT-Enhancer-Binding Protein-beta/metabolism , Aspartic Acid/metabolism , Malates/metabolism , NAD/metabolism , Fibroblasts/metabolism , Glycolysis , Deoxyglucose
2.
PLoS Genet ; 17(11): e1009868, 2021 11.
Article in English | MEDLINE | ID: mdl-34752469

ABSTRACT

While comprehensive molecular profiling of histone H3.3 mutant pediatric high-grade glioma has revealed extensive dysregulation of the chromatin landscape, the exact mechanisms driving tumor formation remain poorly understood. Since H3.3 mutant gliomas also exhibit high levels of copy number alterations, we set out to address if the H3.3K27M oncohistone leads to destabilization of the genome. Hereto, we established a cell culture model allowing inducible H3.3K27M expression and observed an increase in mitotic abnormalities. We also found enhanced interaction of DNA replication factors with H3.3K27M during mitosis, indicating replication defects. Further functional analyses revealed increased genomic instability upon replication stress, as represented by mitotic bulky and ultrafine DNA bridges. This co-occurred with suboptimal 53BP1 nuclear body formation after mitosis in vitro, and in human glioma. Finally, we observed a decrease in ultrafine DNA bridges following deletion of the K27M mutant H3F3A allele in primary high-grade glioma cells. Together, our data uncover a role for H3.3 in DNA replication under stress conditions that is altered by the K27M mutation, promoting genomic instability and potentially glioma development.


Subject(s)
Brain Neoplasms/genetics , DNA Replication/genetics , Genomic Instability , Glioma/genetics , Histones/physiology , Brain Neoplasms/pathology , Child , Gene Expression Regulation, Neoplastic , Glioma/pathology , Humans , Mitosis/genetics
3.
Cell Stem Cell ; 19(3): 383-96, 2016 09 01.
Article in English | MEDLINE | ID: mdl-27424784

ABSTRACT

Umbilical cord blood (CB) is a convenient and broadly used source of hematopoietic stem cells (HSCs) for allogeneic stem cell transplantation. However, limiting numbers of HSCs remain a major constraint for its clinical application. Although one feasible option would be to expand HSCs to improve therapeutic outcome, available protocols and the molecular mechanisms governing the self-renewal of HSCs are unclear. Here, we show that ectopic expression of a single microRNA (miRNA), miR-125a, in purified murine and human multipotent progenitors (MPPs) resulted in increased self-renewal and robust long-term multi-lineage repopulation in transplanted recipient mice. Using quantitative proteomics and western blot analysis, we identified a restricted set of miR-125a targets involved in conferring long-term repopulating capacity to MPPs in humans and mice. Our findings offer the innovative potential to use MPPs with enhanced self-renewal activity to augment limited sources of HSCs to improve clinical protocols.


Subject(s)
Gene Expression Regulation , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/metabolism , MicroRNAs/metabolism , ADP-ribosyl Cyclase 1/metabolism , Animals , Antigens, CD34/metabolism , Cell Proliferation , Cell Self Renewal/genetics , Gene Regulatory Networks , Hematopoietic Stem Cell Transplantation , Humans , Isotope Labeling , Male , Mice, Inbred C57BL , MicroRNAs/genetics , Models, Biological , Multipotent Stem Cells/cytology , Multipotent Stem Cells/metabolism , Multipotent Stem Cells/transplantation , Reproducibility of Results , Time Factors
4.
Stem Cell Reports ; 4(1): 74-89, 2015 Jan 13.
Article in English | MEDLINE | ID: mdl-25434821

ABSTRACT

Accurate monitoring of tumor dynamics and leukemic stem cell (LSC) heterogeneity is important for the development of personalized cancer therapies. In this study, we experimentally induced distinct types of leukemia in mice by enforced expression of Cbx7. Simultaneous cellular barcoding allowed for thorough analysis of leukemias at the clonal level and revealed high and unpredictable tumor complexity. Multiple LSC clones with distinct leukemic properties coexisted. Some of these clones remained dormant but bore leukemic potential, as they progressed to full-blown leukemia after challenge. LSC clones could retain multilineage differentiation capacities, where one clone induced phenotypically distinct leukemias. Beyond a detailed insight into CBX7-driven leukemic biology, our model is of general relevance for the understanding of tumor dynamics and clonal evolution.


Subject(s)
Clonal Evolution/genetics , Leukemia/genetics , Neoplastic Stem Cells/metabolism , Polycomb Repressive Complex 1/genetics , Animals , Bone Marrow Cells/metabolism , Bone Marrow Cells/pathology , Cell Transformation, Neoplastic/genetics , Cluster Analysis , Disease Models, Animal , Disease Progression , Gene Expression , Gene Expression Profiling , Immunophenotyping , Leukemia/pathology , Mice , Neoplastic Stem Cells/pathology , Phenotype
5.
Exp Hematol ; 42(10): 909-18.e1, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25092555

ABSTRACT

MicroRNAs (miRNAs) are crucial for proper functioning of hematopoietic stem and progenitor cells (HSPCs). Members of the miRNA-125 family (consisting of miR-125a, miR-125b1, and miR-125b2) are known to confer a proliferative advantage on cells upon overexpression, to decrease the rate of apoptosis by targeting proapoptotic genes, and to promote differentiation toward the myeloid lineage in mice. However, many distinct biological effects of the three miR-125 species have been reported as well. In the current study, we set out to assess whether the three miRNA-125s that carry identical seed sequences could be functionally different. Our data show that overexpression of each of the three miR-125 family members preserves HSPCs in a primitive state in vitro, results in a competitive advantage upon serial transplantation, and promotes skewing toward the myeloid lineage. All miR-125 family members decreased the pool of phenotypically defined Lin(-)Sca(+)Kit(+)CD48(-)CD150(+) long-term hematopoietic stem cells, simultaneously increasing the self-renewal activity upon secondary transplantation. The downregulation of miR-125s in hematopoietic stem cells abolishes these effects and impairs long-term contribution to blood cell production. The introduction of a point mutation within the miRNA-125 seed sequence abolishes all abovementioned effects and leads to the restoration of normal hematopoiesis. Our results show that all miR-125 family members are similar in function, they likely operate in a seed-sequence-dependent manner, and they induce a highly comparable hematopoietic phenotype.


Subject(s)
Hematopoiesis/genetics , Hematopoietic Stem Cells/metabolism , MicroRNAs/physiology , Animals , Bone Marrow Transplantation , Cell Division , Cell Lineage , Cells, Cultured , Colony-Forming Units Assay , Female , Mice , Mice, Inbred C57BL , MicroRNAs/biosynthesis , MicroRNAs/genetics , Mutagenesis, Site-Directed , Myelopoiesis/genetics , Oligonucleotides/pharmacology , Point Mutation , Radiation Chimera , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Structure-Activity Relationship
6.
J Exp Med ; 211(3): 487-97, 2014 Mar 10.
Article in English | MEDLINE | ID: mdl-24567446

ABSTRACT

Hematopoietic stem cells (HSCs) are able to migrate through the blood stream and engraft bone marrow (BM) niches. These features are key factors for successful stem cell transplantations that are used in cancer patients and in gene therapy protocols. It is unknown to what extent transplanted HSCs distribute throughout different anatomical niches in the BM and whether this changes with age. Here we determine the degree of hematopoietic migration at a clonal level by transplanting individual young and aged mouse HSCs labeled with barcoded viral vector, followed by assessing the skeletal distribution of hundreds of HSC clones. We detected highly skewed representation of individual clones in different bones at least 11 mo after transplantation. Importantly, a single challenge with the clinically relevant mobilizing agent granulocyte colony-stimulating factor (G-CSF) caused rapid redistribution of HSCs across the skeletal compartments. Old and young HSC clones showed a similar level of migratory behavior. Clonal make-up of blood of secondary recipients recapitulates the barcode composition of HSCs in the bone of origin. These data demonstrate a previously unanticipated high skeletal disequilibrium of the clonal composition of HSC pool long-term after transplantation. Our findings have important implications for experimental and clinical and stem cell transplantation protocols.


Subject(s)
Bone Marrow/metabolism , Cell Movement/physiology , Cytokines/metabolism , Hematopoietic Stem Cells/metabolism , Animals , Cell Movement/drug effects , Colony-Forming Units Assay , DNA Barcoding, Taxonomic , Genetic Vectors , Granulocyte Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/physiology , Linear Models , Mice , Mice, Inbred C57BL , Statistics, Nonparametric
7.
Blood ; 122(4): 523-32, 2013 Jul 25.
Article in English | MEDLINE | ID: mdl-23719303

ABSTRACT

The number of hematopoietic stem cells (HSCs) that contributes to blood formation and the dynamics of their clonal contribution is a matter of ongoing discussion. Here, we use cellular barcoding combined with multiplex high-throughput sequencing to provide a quantitative and sensitive analysis of clonal behavior of hundreds of young and old HSCs. The majority of transplanted clones steadily contributes to hematopoiesis in the long-term, although clonal output in granulocytes, T cells, and B cells is substantially different. Contributions of individual clones to blood are dynamically changing; most of the clones either expand or decline with time. Finally, we demonstrate that the pool of old HSCs is composed of multiple small clones, whereas the young HSC pool is dominated by fewer, but larger, clones.


Subject(s)
Aging/blood , Blood Donors , Cell Tracking/methods , Cellular Senescence/physiology , Clonal Evolution/physiology , Hematopoietic Stem Cells/cytology , Age Factors , Animals , Cell Separation/methods , Cells, Cultured , Clone Cells/cytology , Clone Cells/physiology , DNA Barcoding, Taxonomic/methods , DNA Barcoding, Taxonomic/statistics & numerical data , Hematopoietic Stem Cells/physiology , High-Throughput Nucleotide Sequencing , Mice , Mice, Inbred C57BL , Models, Biological , Molecular Typing/methods
8.
Blood ; 115(13): 2610-8, 2010 Apr 01.
Article in English | MEDLINE | ID: mdl-20093403

ABSTRACT

Clonal analysis is important for many areas of hematopoietic stem cell research, including in vitro cell expansion, gene therapy, and cancer progression and treatment. A common approach to measure clonality of retrovirally transduced cells is to perform integration site analysis using Southern blotting or polymerase chain reaction-based methods. Although these methods are useful in principle, they generally provide a low-resolution, biased, and incomplete assessment of clonality. To overcome those limitations, we labeled retroviral vectors with random sequence tags or "barcodes." On integration, each vector introduces a unique, identifiable, and heritable mark into the host cell genome, allowing the clonal progeny of each cell to be tracked over time. By coupling the barcoding method to a sequencing-based detection system, we could identify major and minor clones in 2 distinct cell culture systems in vitro and in a long-term transplantation setting. In addition, we demonstrate how clonal analysis can be complemented with transgene expression and integration site analysis. This cellular barcoding tool permits a simple, sensitive assessment of clonality and holds great promise for future gene therapy protocols in humans, and any other applications when clonal tracking is important.


Subject(s)
Cell Lineage , Clone Cells/chemistry , DNA, Recombinant/analysis , Genetic Markers , Genetic Vectors/genetics , Hematopoietic Stem Cells/chemistry , Oligodeoxyribonucleotides/analysis , Retroviridae/genetics , Sequence Analysis, DNA/methods , Animals , Binomial Distribution , Cell Separation/methods , Flow Cytometry/methods , Genetic Therapy/methods , Genetic Vectors/analysis , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/cytology , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Transgenes , Virus Integration
10.
Blood ; 113(9): 2014-21, 2009 Feb 26.
Article in English | MEDLINE | ID: mdl-18978206

ABSTRACT

Treatment failure in pediatric acute lymphoblastic leukemia (ALL) is related to cellular resistance to glucocorticoids (eg, prednisolone). Recently, we demonstrated that genes associated with glucose metabolism are differentially expressed between prednisolone-sensitive and prednisolone-resistant precursor B-lineage leukemic patients. Here, we show that prednisolone resistance is associated with increased glucose consumption and that inhibition of glycolysis sensitizes prednisolone-resistant ALL cell lines to glucocorticoids. Treatment of prednisolone-resistant Jurkat and Molt4 cells with 2-deoxy-D-glucose (2-DG), lonidamine (LND), or 3-bromopyruvate (3-BrPA) increased the in vitro sensitivity to glucocorticoids, while treatment of the prednisolone-sensitive cell lines Tom-1 and RS4; 11 did not influence drug cytotoxicity. This sensitizing effect of the glycolysis inhibitors in glucocorticoid-resistant ALL cells was not found for other classes of antileukemic drugs (ie, vincristine and daunorubicin). Moreover, down-regulation of the expression of GAPDH by RNA interference also sensitized to prednisolone, comparable with treatment with glycolytic inhibitors. Importantly, the ability of 2-DG to reverse glucocorticoid resistance was not limited to cell lines, but was also observed in isolated primary ALL cells from patients. Together, these findings indicate the importance of the glycolytic pathway in glucocorticoid resistance in ALL and suggest that targeting glycolysis is a viable strategy for modulating prednisolone resistance in ALL.


Subject(s)
Drug Resistance, Neoplasm , Glycolysis/drug effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Prednisolone/therapeutic use , Antineoplastic Agents, Hormonal/pharmacology , Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Daunorubicin/administration & dosage , Deoxyglucose/administration & dosage , Deoxyglucose/pharmacokinetics , Drug Resistance, Neoplasm/drug effects , Drug Resistance, Neoplasm/physiology , Drug Screening Assays, Antitumor , Drug Synergism , Gene Expression Profiling , Gene Expression Regulation, Leukemic/drug effects , Glucocorticoids/administration & dosage , Glucose/metabolism , Glycolysis/genetics , Glycolysis/physiology , Humans , Jurkat Cells , Oligonucleotide Array Sequence Analysis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Prednisolone/pharmacology , Tumor Cells, Cultured , Vincristine/administration & dosage
11.
Blood ; 108(3): 1045-9, 2006 Aug 01.
Article in English | MEDLINE | ID: mdl-16574952

ABSTRACT

Glucocorticoid (GC) resistance is an adverse prognostic factor in childhood acute lymphoblastic leukemia (ALL), but little is known about causes of GC resistance. Up-regulation of the glucocorticoid receptor (GR) has been suggested as an essential step to the induction of apoptosis in leukemic cells. In this study we investigated whether baseline mRNA expression levels of the 5 different GR promoter transcripts (1A1, 1A2, 1A3, 1B, and 1C) or differences in the degree of regulation of the GR or GR promoter transcripts upon GC exposure are related to GC resistance. Therefore, mRNA levels of the 5 GR promoter transcripts and of the GR were measured by quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR; Taqman) technology in primary ALL cells prior to and after 3, 8, and 24 hours of prednisolone exposure. GR expression is induced upon GC exposure in primary ALL patient samples, which is opposite to what is found in tissues in which GCs do not induce apoptosis. GC resistance in childhood ALL cannot be attributed to an inability of resistant cells to up-regulate the expression of the GR upon GC exposure, nor to differences in GR promoter usage (at baseline and upon GC exposure).


Subject(s)
Drug Resistance, Neoplasm , Glucocorticoids/pharmacology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Promoter Regions, Genetic , Receptors, Glucocorticoid/genetics , Up-Regulation/drug effects , Adolescent , Apoptosis/drug effects , Child , Child, Preschool , Female , Gene Expression Regulation, Neoplastic/drug effects , Glucocorticoids/therapeutic use , Humans , Infant , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Prednisolone/pharmacology , RNA, Messenger/analysis , Up-Regulation/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...